undamentalytics Newsletter
Sign in

Relay Therapeutics, Inc. revenue

Relay Therapeutics, Inc.'s revenue was $15.4m in fiscal 2025, up 53.4% on the year before. Since fiscal 2020 ($82.7m) it has grown at a compound -28.6% a year. Over the last twelve months it was $10.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue833126101510
Growth on the year before—−96.3%−54.4%+>999%−60.8%+53.4%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Relay Therapeutics, Inc. $10.3m 23.9% 122.3%
Caribou Biosciences, Inc. $10.0m 10.0% -11.0%
Opus Genetics, Inc. $9.9m -36.1% -39.8%
Mindwalk Holdings Corp. $11.3m 47.8% —
Surrozen, Inc. $11.5m -8.8% —
Apollomics Inc. $8.5m — —

Compare with peers

Head to head: CRBU vs RLAYIRD vs RLAYHYFT vs RLAYRLAY vs SRZN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Relay Therapeutics, Inc.